BioSpace News Archive

U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for direct application system and method for the delivery of bioactive compositions and formulations .

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study.

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.

NJ Biopharmaceuticals LLC, an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey.

A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT treated with a heparin alternative following the Centers for Disease Control and Prevention guidance.

Pandemic leads to decrease in mental healthcare over 2020 calendar year for children and older adults, says State of the Nation’s Mental Health report

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will be presenting at Canaccord Genuity’s 5th Annual Global Cannabis Conference on Tuesday, May 11 th , which is being held virtually this year.

--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis on track for mid-2021--

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 3 of REDWOOD-HCM ( R andomized E valuation of D osing W ith CK-274 in O bstructive O utflow D isease in HCM ), an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69% Growth driven by combination of COVID-related demand, base business strength and acquisition revenue